Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alexander Gomelsky

Urology Gainesville, FL Medical Doctor

NPI 1730105818 CMS profile 412377

1600 Sw Archer Rd, Gainesville, FL 32610

Open in the dashboard

General payments

$6,870

136 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alexander Gomelsky of Gainesville, FL is reported in the CMS Open Payments database as having received $6,870 across 136 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,199 11
2024 General $972 11
2023 General $1,352 24
2022 General $1,333 27
2021 General $375 17
2020 General $293 12
2019 General $1,346 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alexander Gomelsky
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Alexander Gomelsky were reported at $1,199. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Alexander Gomelsky Urology median Middle half National median
2019 $1,346 $480 $147–$1,201 $163
2020 $293 $246 $87–$645 $114
2021 $375 $358 $111–$1,000 $132
2022 $1,333 $476 $143–$1,263 $149
2023 $1,352 $560 $168–$1,461 $160
2024 $972 $563 $170–$1,464 $164
2025 $1,199 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $1,884 20 payments
  2. Cook Medical LLC $840 16 payments
  3. Coloplast Corp $599 9 payments
  4. Boston Scientific Corporation $530 8 payments
  5. Rochester Medical Corporation $458 16 payments
  6. Pfizer Inc. $381 13 payments
  7. Axonics Modulation Technologies, Inc. $327 4 payments
  8. C. R. Bard, Inc. & Subsidiaries $278 10 payments
  9. Intuitive Surgical, Inc. $238 3 payments
  10. Medtronic USA, Inc. $207 5 payments
  11. Other $1,127 32 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,758 126 payments
  2. Travel and Lodging $1,080 9 payments
  3. Gift $32 1 payment
Products named General payments · program years 2019–2025
  1. ALTAVIVA $1,047 9 payments
  2. INTERSTIM Sacral Nerve Stimulation $837 11 payments
  3. Titan $521 6 payments
  4. Cook Medical Urology $381 6 payments
  5. XTANDI $379 12 payments
  6. Axonics $267 2 payments
  7. Da Vinci Surgical System $238 3 payments
  8. Bulkamid $210 3 payments
  9. INTERSTIM Sacral Nerve Stimulation $207 5 payments
  10. Tulsa-Pro $205 1 payment
  11. Other $2,261 65 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

550

Median for Urology: 1,053

Drug cost

$103,351

Median for Urology: $101,464

Branded share of claims

32.2%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 70 $65,189
Gemtesa Vibegron Brand 24 $25,737
Estradiol Generic 37 $2,639
Solifenacin Succinate Generic 52 $1,908
Trospium Chloride Generic 17 $1,689
Tamsulosin Hcl Generic 122 $1,655
Fesoterodine Fumarate Er Fesoterodine Fumarate Brand 14 $1,323
Tolterodine Tartrate Er Tolterodine Tartrate Brand 15 $1,079
Finasteride Generic 78 $1,026
Cefdinir Generic 34 $447

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 59 billing codes

Paid by Medicare

$47,737

Medicare's payments for the services billed

Medicare patients

321

Average age 73

Services billed

685

177 women, 144 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Diabetes 36%
Ischemic heart disease 31%
Chronic kidney disease 29%
Depression 27%
Atrial fibrillation 23%
Heart failure 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

136 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record